RAD 001 (everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia

Journal of Cellular Biochemistry

Volumn 109, Issue 2, 2010, Pages 320-328

  Mancini, Manuela ^a   Petta, Sara ^a   Martinelli, Giovanni ^a   Barbieri, Enza ^a   Santucci, Maria A ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Akt; Chronic myeloid leukemia; mTOR; mTOR inhibitors; RAD 001

Indexed keywords

BCR ABL PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; EVEROLIMUS; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PROTEIN 14 3 3; PROTEIN KINASE B; STRATIFIN; TUBERIN;

ARTICLE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; CYTOTOXICITY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HYDROPHOBICITY; NONHUMAN; NUCLEAR IMPORT; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN BINDING; PROTEIN DEPHOSPHORYLATION; PROTEIN MOTIF;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE; CELL PROLIFERATION; DRUG INTERACTIONS; DRUG RESISTANCE; EXONUCLEASES; FUSION PROTEINS, BCR-ABL; HEMATOPOIESIS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LETHAL DOSE 50; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; MYELOID PROGENITOR CELLS; NEOPLASM PROTEINS; PHOSPHORYLATION; PIPERAZINES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINES; SIROLIMUS; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

MAMMALIA;

EID: 74949100074     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22380     Document Type: Article

References (49)

1. Andreu EJ, Lledò E, Poch E, Ivorra C, Albero MP, Martínez-Climent JA, Montiel-Duarte C, Rifón J, Pérez-Calvo J, Arbona C, Prósper F, Pérez-Roger I. 2005. BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells. Cancer Res 65:3264-3272.
2. Bellodi C, Lidonnici MR, Hamolton A, Helgason GV, Soliera AR, Ronchetti M, Galavotti S, Young KW, Selmi T, Yacobi R, van Etten RA, Donato N, Hunter A, Dinsdale D, Tirrò E, Vigneri P, Nicotera P, Dyer MJ, Holyoake T, Salomoni P, Calabretta B. 2009. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia-chromosome-positive cells, including primary CML stem cells. J Clin Invest 119:1109-1123.
3. Burchert A, Wang Y, Cai D, von Bubnoff N, Paschka P, Muller-Brusselbach S, Ottmann OG, Duyster J, Hochhaus A, Neubauer A. 2005. Compensatory PI3-kinase/Akt/mTOR activation regulates imatinib resistance development. Leukemia 19:1774-1782.
4. Cai SL, Tee AR, Short JD, Bergeron JM, Kim J, Shen J, Guo R, Johnson CL, Kiguchi K, Walker CL. 2006. Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning. J Cell Biol 173:279-289.
5. Carayol N, Katsoulidis E, Sassano A, Altman JK, Druker BJ, Platanias LC. 2008. Suppression of programmed cell death 4 (PDCD4) protein expression by BCR-ABL-regulated engagement of the mTOR/p70S6 kinase pathway. J Biol Chem 283:8601-8610.
6. Daley GQ, Van Etten RA, Baltimore D. 1990. Induction of chronic myelogenous leukemia in mice by the p210 bcr/abl gene of the Philadelphia chromosome. Science 247:824-830.
7. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, larson RA, IRIS Investigators. 2006. Five year follow-up of patients receiving imatinib for chronic myeloid leukaemia. N Engl J Med 355:2408-2417.
8. Frodin M, Antal TL, Dummler BA, Jensen CJ, Deak M, Gammeltoft S, Biondi RM. 2002. A phosphoserine/threonine-binding pocket in AGC kinases and PDK1 mediates activation by hydrophobic motif phosphorylation. EMBO J 21:5396-5407.
9. Han S, Witt RM, Santos TM, Polizzano C, Sabatini BL, Ramesh V. 2008. Pam (Protein associated with Myc) functions as an E3 ubiquitin ligase and regulates TSC/mTOR signalling. Cell Signal 20:1084-1091.
10. Heisterkamp N, Stam K, Groffen J, de Klein A, Grosveld G. 1985. Structural organization of the bcr gene and its role in the Ph0 translocation. Nature 315:758-761.
11. Hong F, Larrea MD, Doughty C, Kwiatkowski DJ, Squillace R, Slingerland JM. 2008. M-TOR-Raptor binds and activates SGK1 to regulate p27 phosphorylation. Mol Cell 30:701-711.
12. Ikezoe T, Nishioka C, Tasaka T, Yang Y, Komatsu N, Togitani K, Koeffler HP, Taguchi H. 2006. The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: Enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling. Mol Cancer Ther 5:2522-2530.
13. Jabbour E, Kantarjian H, Jones D, Talpaz M, Bekele N, O'Brien S, Zhou X, Luthra R, Garcia-Manero G, Giles F, Rios MB, Verstovsek S, Cortes J. 2006. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukaemia treated with Imatinib mesylate. Leukemia 20:1-7.
14. Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, Hall A, Hall MN. 2004. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 6:1122-1128.
15. Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, Jung SY, Huang Q, Qin J, Su B. 2006. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127:125-137.
16. Kim JH, Chu SC, Gramlich JL, Pride YB, Babendreier E, Chauhan D, Salgia R, Podar K, Griffin JD, Sattler M. 2005. Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. Blood 105:1717-1723.
17. Kondo Y, Takao K, Sawaya R, Kondo S. 2005. The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 5:726-734.
18. Li Y, Inoki K, Guan KL. 2004. Biochemical and functional characterization of small GTPase Rheb and TSC2 GAP activity. Mol Cell Biol 24:7965-7975.
19. Liu MY, Cai S, Espejo A, Bedford MT, Walker CL. 2002. 14-3-3 interacts with the tumor suppressor tuberin at Akt phosphorylation sites. Cancer Res 62:6475-6480.
20. Ly C, Arechiga AF, Melo JV, Walsh CM, Ong ST. 2003. Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukaemia cells via the mammalian target of rapamycin. Cancer Res 63:5716-5722.
21. Mancini M, Brusa G, Zuffa E, Corrado P, Martinelli G, Grafone T, Barbieri E, Santucci MA. 2007. Persistent Cdk2 inactivation drives growth arrest of BCR-ABL-expressing cells in response to dual inhibitor of SRC and ABL kinases SKI606. Leuk Res 31:979-987.
22. Mayerhofer M, Valent P, Sperr WR, Griffin JD, Sillaber C. 2002. BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1α, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood 100:3767-3775.
23. Mayerhofer M, Aichberger KJ, Florian S, Krauth MT, Hauswirth AW, Derdak S, Sperr WR, Esterbauer H, Wagner O, Marosi C, Pickl WF, Deininger M, Weisberg E, Druker BJ, Griffin JD, Sillaber C, Valent P. 2005. Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: Dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cells. FASEB J 19:960-962.
24. Mazzacurati L, Pattacini L, Brusa G, Mancini M, Benvenuti M, Barbieri E, Martinelli G, Baccarani M, Greeberger JS, Santucci MA. 2004. Chk2 drives late G1/early S phase arrest of clonal myeloid progenitors expressing the p210 BCR-ABL tyrosine kinase in response to STI571. Hematol J 5:168-177.
25. Mohi MG, Boulton C, Gu TL, Sternberg DW, Neuberg D, Griffin JD, Gilliland DG, Neel BG. 2004. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci USA 101:3130-3135.
26. Navé BT, Ouwens M, Withers DJ, Alessi DR, Shepherd PR. 1999. Mammalian target of rapamycin is a direct target for protein kinase B: Identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem J 344:427-431.
27. O'Reilly K, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, Baselga J, Rosen N. 2006. mTOR inhibition induces upstream receptor tyrosine kinase signalling and activates Akt. Cancer Res 66:1500-1508.
28. Prabhu S, Saadat D, Zhang M, Halbur L, Fruehauf JP, Ong ST. 2007. A novel mechanism for Bcr-Abl action: Bcr-Abl-mediated induction of the eIF4F translation initiation complex and mRNA translation. Oncogene 26:1188-1200.
29. Rosner M, Hengstschläger M. 2004. Tuberin binds p27 and negatively regulates its interaction with the SCF component Skp2. J Biol Chem 279:48707-48715.
30. Rosner M, Freilinger A, Hengstschlager M. 2007a. Akt regulates nuclear/cytoplasmatic localization of tuberin. Oncogene 26:521-531.
31. Rosner M, Freilinger A, Hanneder M, Fujita N, Lubec G, Tsuruo T, Hengstschläger M. 2007b. P27Kip1 localization depends on the tumor suppressor protein tuberin. Hum Mol Genet 16:1541-1556.
32. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. 2005. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307:1098-1101.
33. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhand AL, Sabatini DM. 2006. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 22:159-168.
34. Sekimoto T, Fukumoto M, Yoneda Y. 2004. 14-3-3 suppresses the nuclear localization of threonine 157-phosphorylated p27(Kip1). EMBO J 23:1934-1942.
35. Shi Y, Yan H, Frost P, Gera J, Lichtenstein A. 2005. Mammalian target of rapamycin inhibitors activate AKT kinase in multiple myeloma cells by upregulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol Cancer Ther 4:1533-1540.
36. Shor B, Zhang WG, Toral-Barza L, Lucas J, Abraham RT, Gibbons JJ, Yu K. 2008. A new pharmacological action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis. Cancer Res 68:2934-2943.
37. Sillaber C, Mayerhofer M, Bohm A, Vales A, Gruze A, Aichberger KJ, Esterbauer H, Pfeilstocker M, Sperr WR, Pickl WF, Haas OA, Valent P. 2008. Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia. Eur J Clin Invest 38:43-52.
38. Tabernero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K, Martinelli E, Ramon y Cajal S, Jones S, Vidal L, Shand N, Macarulla T, Ramos FJ, Dimitrijevic S, Zoellner U, Tang P, Stumm M, Lane HA, Lebwohl D, Baselga J. 2008. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: A phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 26:1603-1610.
39. Tamburini J, Chapuis N, Bardet V, Park S, Sujobert P, Willems L, Ifrah N, Dreyfus F, Mayeux P, Lacombe C, Bouscary D. 2008. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signalling in acute myeloid leukaemia: Rationale for therapeutic inhibition of both pathways. Blood 111:379-382.
40. Wan X, Harkavy B, Shen N, Grohar P, Helman LJ. 2007. Rapamycin induces feedback activation of Akt signalling through an IGF-1R-dependent mechanism. Oncogene 26:1932-1940.
41. Wang L, Harris TE, Roth RA, Lawrence JC, Jr. 2007. PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding. J Biol Chem 282:20036-20044.
42. Wang X, Yue P, Kim YA, Fu H, Khuri FR, Sun SY. 2008. Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/Raptor inhibition-initiated, mTOR/Rictor-independent Akt activation. Cancer Res 68:7409-7418.
43. Wieman HL, Wofford JA, Rathmell JC. 2007. Cytokine stimulation promotes glucose uptake via phosphatidylinositol-3 kinase/Akt regulation of Glut1 activity and trafficking. Mol Biol Cell 18:1437-1446.
44. Woo SY, Kim DH, Jun CB, Kim YM, Haar EV, Lee S, Hegg JW, Bandhakavi S, Griffin TJ, Kim DH. 2007. PRR5, a novel component of mTOR complex 2, regulates platelet-derived growth factor receptor beta expression and signalling. J Biol Chem 282:25604-25612.
45. Wullschleger S, Loewith R, Hall MN. 2006. TOR signalling in growth and metabolism cell. 124:471-484.
46. Yee KWL, Zeng Z, Konopleva M, Verstovsek S, Ravandi F, Ferrajoli A, Thomas D, Wierda W, Apostolidou E, Albitar M, O'Brien S, Andreeff M, Giles FJ. 2006. Phase I/II study of the mammalian target of rapamycin inhibitor Everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 12:5164-5173.
47. Yilmaz OH, Valdez RV, Theisen BK, Guo W, Ferguson DO, Wu H, Morrison SJ. 2006. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 441:475-482.
48. Zeng Z, Sarbassov DD, Samudio IJ, Yee KW, Munsell MF, Ellen Jackson C, Giles FJ, Sabatini DM, Andreeff M, Konopleva M. 2007. Rapamycin derivatives reduce mTORC2 signaling and inhibit activation in AML. Blood 109:3509-3512.
49. Zhang M, Fu W, Prabhu S, Moore JC, Ko J, Kim JW, Druker BJ, Trapp V, Fruehauf J, Gram H, Fan HY, Ong ST. 2008. Inhibition of polysome assembly enhances imatinib activity against chronic myelogenous leukemia and overcomes imatinib resistance. Mol Cell Biol 28:6496-6509.